KemPharm, Inc. (KMPH) Insider Acquires $10,400.00 in Stock
KemPharm, Inc. (NASDAQ:KMPH) insider Gordon K. Johnson purchased 4,000 shares of KemPharm stock in a transaction dated Thursday, August 24th. The stock was acquired at an average price of $2.60 per share, with a total value of $10,400.00. Following the acquisition, the insider now owns 3,000 shares in the company, valued at approximately $7,800. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of KemPharm, Inc. (NASDAQ:KMPH) traded up 1.85% on Monday, hitting $2.75. 1,828 shares of the stock were exchanged. The stock’s market cap is $40.31 million. KemPharm, Inc. has a 52-week low of $2.45 and a 52-week high of $5.40. The company’s 50 day moving average is $3.24 and its 200-day moving average is $3.86.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.19. Analysts predict that KemPharm, Inc. will post ($2.72) EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of KemPharm during the first quarter worth about $647,000. Finally, C WorldWide Group Holding A S raised its position in shares of KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock worth $890,000 after buying an additional 16,699 shares during the last quarter. Hedge funds and other institutional investors own 40.01% of the company’s stock.
Several research firms have recently commented on KMPH. Oppenheimer Holdings, Inc. set a $13.00 price target on shares of KemPharm and gave the company a “buy” rating in a report on Thursday, August 10th. Canaccord Genuity set a $7.00 price target on shares of KemPharm and gave the company a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research lowered shares of KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. ValuEngine lowered shares of KemPharm from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $8.00 price target on shares of KemPharm in a report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. KemPharm presently has an average rating of “Buy” and a consensus target price of $8.10.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.